<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367675</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 06019</org_study_id>
    <secondary_id>842686</secondary_id>
    <nct_id>NCT04367675</nct_id>
  </id_info>
  <brief_title>INO 5401 Vaccination in BRCA1/2 Mutation Carriers</brief_title>
  <official_title>Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adults With BRCA1 or BRCA2 Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research study is being conducted to test an experimental vaccine to potentially prevent
      cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe
      (without significant side effects) and test a new way of administering vaccines. It will also
      test whether the vaccine activates your immune system.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicities</measure>
    <time_frame>for 2 years after last dose of study treatment</time_frame>
    <description>Dose-limiting toxicities will be classified by system organ class (SOC), preferred term (PT), severity, and relationship to Study Treatment, and graded in accordance with Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antigen-specific cellular immune responses</measure>
    <time_frame>for 2 years after last dose of study treatment</time_frame>
    <description>Defined as &gt;2-fold increase in spot-forming units (SFU) relative to baseline at any mid-treatment or post-treatment time point, in any antigen-specific T cell as measured by ELISPOT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>BRCA1 Mutation</condition>
  <arm_group>
    <arm_group_label>INO-5401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive INO-5401 9mg DNA vaccine on Day 1 of Weeks 4, 8, and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INO-5401 and INO-9012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive INO-5401 9mg DNA and INO-09012 1 mg DNA vaccine on Day 1 of Weeks 4, 8, and 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INO-5401</intervention_name>
    <description>9mg DNA</description>
    <arm_group_label>INO-5401</arm_group_label>
    <arm_group_label>INO-5401 and INO-9012</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INO-9012</intervention_name>
    <description>1mg DNA</description>
    <arm_group_label>INO-5401 and INO-9012</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Carrier of a pathogenic or likely pathogenic mutation in BRCA1 or BRCA2;

          -  With or without prior prophylactic (but not therapeutic) mastectomy or
             salpingo-oophorectomy;

          -  Minimum of two clear sites on the skin to allow for injection. Sites must be without
             tattoos, scars, or active lesions/rashes within 2 cm of intended injection site;

          -  ECOG (Eastern Cooperative Oncology Group) performance status of 0;

          -  Normal ECG or ECG without clinically significant findings and which does not require
             clinical action;

          -  Normal bone marrow, hepatic, and renal function. ANC (Absolute Neutrophil Count) ≥
             1.5x109 cell/ml, platelets ≥150,000 /mm3, hemoglobin ≥11.0 g/dL, normal concentrations
             of total serum bilirubin, AST, ALT, CPK alkaline phosphatase, serum creatinine, and
             PT-INR/PTT.

        Exclusion Criteria:

          -  Previous treatment with INO-5401 or IL-12 containing therapy, or any other DNA
             immunotherapy

          -  Prior history of invasive cancer.

          -  Participation in other studies involving investigational drug(s) within 4 weeks prior
             to study entry and/or during study participation

          -  Cardiac pre-excitation syndromes, e.g. Wolff-Parkinson-White syndrome;

          -  Prior major surgery within 4 weeks of first Study Treatment.

          -  Presence of acute or chronic bleeding or clotting disorder that would contraindicate
             IM injections, or use of blood thinners within 2 weeks of first study treatment

          -  Any concurrent condition requiring the continued or anticipated use of systemic
             steroids or immunosuppressive therapy

          -  History of clinically significant autoimmune disease or other immunosuppressive
             disease;

          -  HIV infection; Known history of hepatitis B and/or hepatitis C with active viral
             replication

          -  Receipt of any blood product within 2 weeks before signing the ICF;

          -  Administration of any vaccine, except the influenza vaccine, within 4 weeks of the
             first study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Domchek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carey Kokkonen</last_name>
    <phone>215-220-9782</phone>
    <email>carey.kokkonen@pennmedicine.upenn.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

